STOCK TITAN
  1. Home
  2. Sec-filings
  3. MDWD
  4. [6-K] MediWound Ltd. Current Report (Foreign Issuer)

BARDA’s up-to-$197M NexoBrid contract highlighted by MediWound (MDWD)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

MediWound Ltd. reports that its North America distributor Vericel has been awarded a ten-year BARDA contract valued at up to $197 million related to burn treatment product NexoBrid.

According to Vericel, the contract covers NexoBrid procurement for the U.S. Strategic National Stockpile, a Vendor Managed Inventory system, development of a next generation formulation, an additional indication such as blast trauma injuries, and design and validation of a potential U.S.-based manufacturing facility.

Vericel reported that the base period totals $35 million, including about $10 million over the next 12 months for initial NexoBrid procurement and VMI establishment. MediWound notes these statements are based on Vericel’s reports and highlights typical clinical, regulatory, commercial and BARDA-related uncertainties.

Positive

  • None.

Negative

  • None.

Insights

BARDA’s up-to-$197M NexoBrid contract via Vericel deepens U.S. government backing but has staged, uncertain execution.

The disclosed BARDA arrangement centers on NexoBrid, MediWound’s enzymatic burn debridement biologic, with Vericel holding exclusive North American distribution rights. Vericel reports a ten-year contract of up to $197 million, including a $35 million base period, partly for Strategic National Stockpile purchases and Vendor Managed Inventory services.

The contract structure spreads value over time and includes options for further procurement, expanded blast trauma indications, and a potential U.S. manufacturing facility, so realized economics depend on option exercises and development progress. MediWound stresses that details originate from Vericel and emphasizes typical biopharma risks around regulatory approvals, clinical work and market adoption in its cautionary language.

BARDA contract headline value $197 million Ten-year contract value for NexoBrid-related activities reported by Vericel
Base period contract $35 million Initial base period of BARDA contract reported by Vericel
Initial 12‑month procurement and VMI $10 million Approximate amount over next 12 months for initial NexoBrid procurement and VMI
Contract duration 10 years Length of BARDA contract effective as of April 1, 2026
Vendor Managed Inventory (VMI) financial
"the contract is for the procurement of NexoBrid, establishment and maintenance of a Vendor Managed Inventory (VMI) system"
Strategic National Stockpile regulatory
"initial procurement of NexoBrid for the U.S. Strategic National Stockpile and VMI establishment"
A strategic national stockpile is a government-held reserve of critical medical supplies, medicines, vaccines and equipment kept to respond quickly to public health emergencies. For investors, it matters because government purchases, replenishment schedules and stockpile policies can create sudden demand, long-term contracts or regulatory priorities that directly affect makers, distributors and suppliers of those goods—think of it as a national emergency pantry that can drive corporate revenue and risk.
orphan drug medical
"NexoBrid is a topically administered, biological orphan drug for the enzymatic removal of eschar"
A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.
blast trauma injuries medical
"initial development activities for a potential expanded NexoBrid indication for the treatment of blast trauma injuries"
Blast trauma injuries are the physical harm caused by an explosion’s sudden pressure wave, flying debris, heat and subsequent impacts, producing a mix of wounds to organs, lungs, ears, skin and bones—imagine the combined effect of a powerful shock, shrapnel and a hard fall all at once. Investors should care because these injuries drive hospital demand, long-term care costs, regulatory scrutiny and potential liability for industries tied to explosives, safety equipment, military and energy operations.
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Form 6-K: How Foreign Companies Report to the SEC →

SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
______________________
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
 
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
 
For the month of April 2026
 
Commission File Number: 001-36349
 
MediWound Ltd.
(Translation of registrant’s name into English)
 
42 Hayarkon Street
Yavne, 8122745 Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
Form 20-F ☒ Form 40-F ☐
 
EXPLANATORY NOTE

On April 2, 2026, MediWound Ltd. (the “Company”) issued a press release entitled “MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million”. A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

The contents of this Form 6-K (including the information contained in Exhibit 99.1) are hereby incorporated by reference into the Company’s Registration Statements on (i) Form S-8, filed with the Securities and Exchange Commission (the “SEC”) on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022, August 15, 2023, March 19, 2025 and March 5, 2026 (Registration Nos. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697, 333-273997, 333-285897, and 333-294055, respectively), and (ii) Form F-3, filed with the SEC on August 29, 2024 and March 19, 2025 (Registration Nos. 333-281843 and 333-285908, respectively).

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Date: April 2, 2026
MEDIWOUND LTD.
 
By: /s/ Hani Luxenburg
Name: Hani Luxenburg
Title: Chief Financial Officer

EXHIBIT INDEX

The following exhibit is filed as part of this Form 6-K:

Exhibit Description

99.1
Press release dated April 2, 2026 titled “MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million”.

Exhibit 99.1

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
 
YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation (NASDAQ:VCEL), its exclusive distributor of NexoBrid® in North America, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
 
Vericel reported that the contract is for the procurement of NexoBrid, establishment and maintenance of a Vendor Managed Inventory (VMI) system, design and validation of a U.S.-based manufacturing facility, and the development of a next generation formulation and additional indication for NexoBrid.
 
Vericel further reported that the base period contract of $35 million includes approximately $10 million over the next 12 months for the initial procurement of NexoBrid for the U.S. Strategic National Stockpile and VMI establishment, funding for VMI-related services and initial development activities for a potential expanded NexoBrid indication for the treatment of blast trauma injuries.
 
According to Vericel, the ten-year contract, effective as of April 1, 2026, also includes optional awards for additional NexoBrid procurement to expand the Strategic National Stockpile, further clinical development for a potential blast trauma indication, design and validation of a potential U.S.-based manufacturing facility and the development and procurement of a room temperature stable formulation of NexoBrid.
 
About NexoBrid®
 
NexoBrid is a topically administered, biological orphan drug for the enzymatic removal of eschar in patients with deep partial- and full-thickness thermal burns. It selectively removes non-viable tissue while preserving viable tissue and is approved for use in adults and pediatric patients in over 40 countries, including the United States, European Union, and Japan.
 
NexoBrid development has been supported with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), under contract HHSO100201500035C.About MediWound Ltd.
 
About MediWound
 
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx®, is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management.
 
For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).
 
Cautionary Note Regarding Forward-Looking Statements
 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause MediWound’s actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are based on current expectations, estimates, forecasts and projections about future events and are subject to a number of risks and uncertainties, many of which are beyond our control.
This press release is based, in part, on information reported by Vericel Corporation, MediWound’s exclusive distributor of NexoBrid® in North America, regarding its contract with BARDA, and MediWound has not independently verified such information.
Forward-looking statements can be identified by words such as “anticipates,” “intends,” “plans,” “expects,” “believes,” “estimates,” “potential,” “will,” “would,” “should,” “could,” “may,” and similar expressions. In particular, this press release contains forward-looking statements regarding the expected benefits related to the BARDA contract awarded to Vericel, including potential procurement of NexoBrid®, development activities, and the potential impact on MediWound.
Factors that could cause actual results to differ materially include, but are not limited to: uncertainties related to the timing, scope and extent of BARDA procurement and the exercise of contract options; MediWound’s relationship with Vericel and its role under the distribution agreement; risks related to regulatory approvals and clinical development activities; the inherent uncertainties associated with the development and commercialization of biopharmaceutical products; market acceptance of our products; competition; our ability to manufacture and supply our products; and other factors described in MediWound’s filings with the U.S. Securities and Exchange Commission (“SEC”), including in our Annual Report on Form 20-F for the year ended December 31, 2025, filed on March 5, 2026, and subsequent reports on Form 6-K.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. MediWound undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

MediWound Contacts:
      
       
Hani Luxenburg
Chief Financial Officer
MediWound Ltd.
ir@mediwound.com
  
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
  

Source: View Original Filing on SEC EDGAR

FAQ

How much is the base period of the BARDA NexoBrid contract reported by Vericel?

Vericel reported a base period contract of $35 million. This includes about $10 million over the next 12 months for initial NexoBrid procurement for the U.S. Strategic National Stockpile, establishing Vendor Managed Inventory, and initial development work for a blast trauma indication.

What potential uses of NexoBrid are included in the BARDA contract described by MediWound (MDWD)?

The contract reported by Vericel includes procurement of NexoBrid for thermal burns and development activities for a potential expanded indication in blast trauma injuries. It also covers work on a next generation formulation and a room temperature stable version, alongside U.S.-based manufacturing design.

What is NexoBrid according to MediWound’s Form 6-K disclosure?

NexoBrid is described as a topically administered biological orphan drug that enzymatically removes eschar in deep partial- and full-thickness thermal burns. It selectively removes non-viable tissue while preserving viable tissue and is approved for adults and pediatric patients in the U.S., EU, Japan and other markets.

Filing Exhibits & Attachments

1 document

Press Releases